Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Inari Medical, Inc. (NARI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
59.62-0.47 (-0.78%)
At close: 04:00PM EDT
59.62 0.00 (0.00%)
After hours: 04:17PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close60.09
Open59.59
Bid59.64 x 1100
Ask59.64 x 800
Day's Range58.01 - 61.62
52 Week Range50.50 - 100.00
Volume716,673
Avg. Volume828,609
Market Cap2.993B
Beta (5Y Monthly)N/A
PE Ratio (TTM)209.93
EPS (TTM)0.28
Earnings DateMar 07, 2022 - Mar 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.67
  • GlobeNewswire

    Inari Medical Announces Launch of 2021 Ethos and Sustainability Report

    IRVINE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the publication of its first ever “Ethos and Sustainability Report.” The report highlights Inari’s commitment to its ethos, and as part of that to environmental, social and governance (ESG) leadership. The report can be found on Inari’s website here. “I am proud to is

  • Zacks

    Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

    Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

  • Benzinga

    Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus

    View more earnings on NARISee more from BenzingaQuidel Clocks More Than Three-Fold Jump In COVID-19 ProductsPacific Biosciences Clocks 14% Jump In Q1 RevenuesDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement
Advertisement